Company’s 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PAVM is 9.73M, and currently, short sellers hold a 2.70% ratio of that floaft. The average trading volume of PAVM on February 28, 2025 was 225.35K shares.
PAVM) stock’s latest price update
PAVmed Inc (NASDAQ: PAVM)’s stock price has gone rise by 10.00 in comparison to its previous close of 0.71, however, the company has experienced a 0.13% increase in its stock price over the last five trading days. prnewswire.com reported 2025-02-27 that Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK, Feb. 27, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospitals (UH), has been awarded an $8 million National Institutes of Health (NIH) R01 grant to conduct a five-year clinical study designed to evaluate esophageal precancer detection using Lucid’s EsoCheck® Esophageal Cell Collection Device and EsoGuard® Esophageal DNA Test among at-risk individuals without symptoms of chronic gastroesophageal reflux disease (GERD). The study, “A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett’s Esophagus and Its Progression,” aims to evaluate the effectiveness of EsoCheck and EsoGuard in detecting esophageal precancer (Barrett’s Esophagus or BE) to prevent esophageal cancer (EAC) within a non-GERD at-risk population.
PAVM’s Market Performance
PAVM’s stock has risen by 0.13% in the past week, with a monthly rise of 21.29% and a quarterly drop of -21.90%. The volatility ratio for the week is 11.53% while the volatility levels for the last 30 days are 11.51% for PAVmed Inc The simple moving average for the past 20 days is 9.03% for PAVM’s stock, with a -21.84% simple moving average for the past 200 days.
Analysts’ Opinion of PAVM
Many brokerage firms have already submitted their reports for PAVM stocks, with Cantor Fitzgerald repeating the rating for PAVM by listing it as a “Overweight.” The predicted price for PAVM in the upcoming period, according to Cantor Fitzgerald is $8 based on the research report published on March 30, 2021 of the previous year 2021.
Ascendiant Capital Markets, on the other hand, stated in their research note that they expect to see PAVM reach a price target of $5. The rating they have provided for PAVM stocks is “Buy” according to the report published on November 05th, 2020.
Maxim Group gave a rating of “Buy” to PAVM, setting the target price at $5 in the report published on June 28th of the previous year.
PAVM Trading at 16.32% from the 50-Day Moving Average
After a stumble in the market that brought PAVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.69% of loss for the given period.
Volatility was left at 11.51%, however, over the last 30 days, the volatility rate increased by 11.53%, as shares surge +21.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.13% upper at present.
During the last 5 trading sessions, PAVM rose by +0.13%, which changed the moving average for the period of 200-days by -65.29% in comparison to the 20-day moving average, which settled at $0.7163. In addition, PAVmed Inc saw 24.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PAVM starting from JAMES L. COX, who proposed sale 9,469 shares at the price of $0.78 back on Dec 12 ’24. After this action, JAMES L. COX now owns shares of PAVmed Inc, valued at $7,380 using the latest closing price.
JAMES L. COX, the Director of PAVmed Inc, proposed sale 38,095 shares at $0.86 during a trade that took place back on Dec 09 ’24, which means that JAMES L. COX is holding shares at $32,739 based on the most recent closing price.
Stock Fundamentals for PAVM
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.99 for the gross margin
The net margin for PAVmed Inc stands at 6.03. The total capital return value is set at 7.95.
Based on PAVmed Inc (PAVM), the company’s capital structure generated 1.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.3. The debt to equity ratio resting at -7.17. The interest coverage ratio of the stock is -960.02.
Currently, EBITDA for the company is -75.74 million with net debt to EBITDA at 2.9. When we switch over and look at the enterprise to sales, we see a ratio of 10.61. The receivables turnover for the company is 252.12for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.06.
Conclusion
In a nutshell, PAVmed Inc (PAVM) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
